Theme
Metabolic disease
Diabetes, NASH, and related conditions targeted by incretin and metabolic drugs.
Metabolic disease spans diabetes, NASH, and related conditions driven by impaired energy regulation. Incretin and other metabolic drugs are increasingly applied across these overlapping indications.
Companies · 8
Alnylam Pharmaceuticals, Inc.ALNY
Market cap$19B
Conviction5 / 5
RNA therapeuticsMetabolic disease
Read profileAstraZeneca PLCAZN
Market cap$270B
Conviction4 / 5
Metabolic disease
Read profileRegeneron Pharmaceuticals, Inc.REGN
Market cap$94B
Conviction4 / 5
Metabolic disease
Read profileMadrigal Pharmaceuticals, Inc.MDGL
Market cap$8.8B
Conviction4 / 5
Metabolic diseaseObesity
Read profileBachem Holding AGBANB
Market cap$6.8B
Conviction4 / 5
GLP-1Metabolic disease
Read profileGilead Sciences, Inc.GILD
Market cap$206B
Conviction3 / 5
Metabolic disease
Read profileViking Therapeutics, Inc.VKTX
Market cap$3.2B
Conviction3 / 5
ObesityMetabolic disease
Read profileScholar Rock Holding CorporationSRRK
Market cap$5.9B
Conviction2 / 5
Metabolic disease
Read profile